Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
about
Gaucher disease and comorbidities: B-cell malignancy and parkinsonismGlucocerebrosidase and Parkinson disease: Recent advancesConverging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's diseaseThe relationship between glucocerebrosidase mutations and Parkinson diseaseA Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsAtypical juvenile presentation of GM2 gangliosidosis AB in a patient compound-heterozygote for c.259G > T and c.164C > T mutations in the GM2A gene.Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.Gaucher-Associated Parkinsonism.Glucocerebrosidase activity in Parkinson's disease with and without GBA mutationsApplications of iPSC-derived models of Gaucher disease[More than expectorant: new scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases].ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation AnalysisA new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice.Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson diseaseProgress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Endoplasmic reticulum and lysosomal Ca²⁺ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts.Basic science breaks through: New therapeutic advances in Parkinson's disease.GBA mutations in Parkinson disease: earlier death but similar neuropathological features.Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.The renal Fanconi syndrome in cystinosis: pathogenic insights and therapeutic perspectives.Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.New Directions in Gaucher Disease.Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.Autophagy as an Emerging Common Pathomechanism in Inherited Peripheral Neuropathies.Non-motor features of Parkinson disease.Glucocerebrosidase Mutations in Parkinson Disease.Survival and dementia in GBA-associated Parkinson's disease: The mutation matters.Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers.Glucocerebrosidase enzyme activity in GBA mutation Parkinson's diseaseProtective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.Ambroxol for the treatment of fibromyalgia: science or fiction?Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.Enzyme enhancers for the treatment of Fabry and Pompe disease.
P2860
Q27002301-C47AF134-1B99-49A3-AA56-78430E3B6242Q27005669-4B6F6AA6-C17C-4C73-8711-F318F8761F89Q28074143-0960AA60-6C3E-4AE5-9EF0-03B88BFAE57CQ28077257-82BD3E8C-2E0B-46A6-B0DC-30CA29F8BFB1Q30235844-9942EC93-237B-4111-A1C1-C5BB85D66C06Q33555786-877CAB05-240B-479C-92CC-636109CC9D89Q33835745-1517484C-63E1-4324-8E5D-1CC86FE68B94Q35596071-3D7AB0DC-A345-47AD-B7BF-7D96C304DE53Q35822086-92DA2CC8-C00F-4230-8603-E86DEB8DED7DQ35851610-E184A75B-A7F5-4B82-A734-5D38AD1FABEFQ36041420-749C3923-BFA2-4658-ABBE-12CE66D561E4Q36352522-A4AF2A67-4C5F-4E1B-866F-4FEF368008A8Q36413065-A83DDB6B-E0FD-4C0A-A6F7-D0F05E2AD0CEQ36678823-AEE1F6FB-C4C9-4C07-BA49-6C2793E5ECD9Q36885946-CB18B7E7-EDCD-4F1C-9CE5-F77AB0283A8CQ37120413-C48F3B18-170C-4A3A-A9EF-33AA0346E44EQ37189019-C58F1972-D5A1-407E-ABE7-2E9C6E40A55DQ37462136-C16FCC2B-6414-42D7-803F-23932B375A5AQ37528927-CB1B37EE-9EF3-43A8-863F-FD1FECF308A7Q37738863-E9A3B47C-3DBC-492F-B416-CB7867FDB903Q38389995-BA1E8601-83B7-42B4-85B8-C8E6F0D526D2Q38547662-151FBF46-A3CA-46E6-901E-5D4BAFAD4982Q38611816-88FA39D1-C33D-4F0B-9F57-A9F75091A279Q38727638-C9E317AF-3619-4E83-9A89-484E4739F987Q38765856-A487BD2A-4581-4E64-82F8-DDBA3BA87FC6Q38781097-D6C54DC4-CCF7-4CDC-85EF-A5339F4A8532Q38811401-E7687C42-E52E-434F-9895-1FC651B9EFDCQ38905996-13F50A22-2359-4A09-AE1C-499F51BB60CFQ38927256-CA770CF6-B847-46E7-B344-6D6D364177ABQ39148146-A86027BB-17E5-4FD0-9762-1EA697086EABQ39335586-77EE2EBE-D97E-4896-BB28-2D62023C4532Q39358549-58FB0C2F-9831-4AD0-A926-59175958BB9BQ39362339-5B1B352A-8C4A-42F7-91DE-EB551D2C99D2Q39386374-7474CB88-9913-4D7F-904C-CCE1A86833B8Q40114382-2E2B8267-244A-4352-A2E7-F78CF5571D7EQ40994106-B3E01667-8C06-4011-B2A8-2312C6C52A8BQ41126307-241A7F31-73E0-4723-9FE5-A2E56786A025Q41483222-0AF6646B-EA7E-4529-A832-5CA6054D8298Q41623081-652629AD-D928-403C-B051-A59F18EDDB04Q42018342-563F6FC6-6950-417E-8326-B2F0766E4F8C
P2860
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@ast
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@en
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@nl
type
label
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@ast
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@en
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@nl
prefLabel
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@ast
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@en
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Ambroxol improves lysosomal bi ...... linked Parkinson disease cells
@en
P2093
Alisdair McNeill
Anthony H V Schapira
Atul Mehta
J Mark Cooper
Tom Foltynie
P2860
P304
P3181
P356
10.1093/BRAIN/AWU020
P407
P577
2014-05-01T00:00:00Z